A major challenge in human genetics is to devise a systematic strategy to integrate disease-associated variants with diverse genomic and biological data sets to provide insight into disease pathogenesis and guide drug discovery for complex traits such as rheumatoid arthritis (RA) 1 . Here we performed a genome-wide association study meta-analysis in a total of .100,000 subjects of European and Asian ancestries (29, 880 RA cases and 73,758 controls), by evaluating 10 million single-nucleotide polymorphisms. We discovered 42 novel RA risk loci at a genome-wide level of significance, bringing the total to 101 (refs 2-4) . We devised an in silico pipeline using established bioinformatics methods based on functional annotation 5 , cis-acting expression quantitative trait loci 6 and pathway analyses 7-9 -as well as novel methods based on genetic overlap with human primary immunodeficiency, haematological cancer somatic mutations and knockout mouse phenotypes-to identify 98 biological candidate genes at these 101 risk loci. We demonstrate that these genes are the targets of approved therapies for RA, and further suggest that drugs approved for other indications may be repurposed for the treatment of RA. Together, this comprehensive genetic study sheds light on fundamental genes, pathways and cell types that contribute to RA pathogenesis, and provides empirical evidence that the genetics of RA can provide important information for drug discovery.
We conducted a three-stage trans-ethnic meta-analysis (Extended Data Fig. 1 ). On the basis of the polygenic architecture of RA 10 and shared genetic risk among different ancestry 3, 4 , we proposed that combining a genome-wide association study (GWAS) of European and Asian ancestry would increase power to detect novel risk loci. In stage 1, we combined 22 GWAS for 19,234 cases and 61,565 controls of European and Asian ancestry [2] [3] [4] . We performed trans-ethnic, European-specific and Asian-specific GWAS meta-analysis by evaluating ,10 million single-nucleotide polymorphisms (SNPs) 11 . Characteristics of the cohorts, genotyping platforms and quality control criteria are described in Extended Data Table 1 (overall genomic control inflation factor l GC , 1.075).
Stage 1 meta-analysis identified 57 loci that satisfied a genome-wide significance threshold of P , 5.0 3 10 28 , including 17 novel loci (Extended Data Fig. 2 ). We then conducted a two-step replication study (stage 2 for in silico and stage 3 for de novo) in 10,646 RA cases and 12, 193 controls for the loci with P , 5.0 3 10 26 in stage 1. In a combined analysis of stages 1-3, we identified 42 novel loci with P , 5.0 3 10 28 in any of the trans-ethnic, European or Asian meta-analyses. This increases the total number of RA risk loci to 101 (Table 1 and Supplementary  Table 1 ).
Comparison of 101 RA risk loci revealed significant correlations of risk allele frequencies (RAFs) and odds ratios (ORs) between Europeans and Asians (Extended Data Fig. 3a -c; Spearman's r 5 0.67 for RAF and 0.76 for OR; P , 1.0 3 10 213 ), although five loci demonstrated population-specific associations (P , 5.0 3 10 28 in one population but P . 0.05 in the other population without overlap of the 95% confidence intervals (95% CIs) of the ORs). In the population-specific genetic risk model, the 100 RA risk loci outside of the major histocompatibility complex (MHC) region 12 explained 5.5% and 4.7% of heritability in Europeans and Asians, respectively, with 1.6% of the heritability explained by the novel loci. The trans-ethnic genetic risk model, based on the RAF from one population but the OR from the other population, could explain the majority (.80%) of the known heritability in each population (4.7% for Europeans and 3.8% for Asians). These observations support our hypothesis that the genetic risk of RA is shared, in general, among Asians and Europeans.
We assessed enrichment of 100 non-MHC RA risk loci in epigenetic chromatin marks 13 (Extended Data Fig. 3d ). Of 34 cell types investigated, we observed significant enrichment of RA risk alleles with trimethylation of histone H3 at lysine 4 (H3K4me3) peaks in primary CD4 1 regulatory T cells (T reg cells; P , 1.0 3 10 25 ). For the RA risk loci enriched with T reg H3K4me3 peaks, we incorporated the epigenetic annotations along with trans-ethnic differences in patterns of linkage disequilibrium to fine-map putative causal risk alleles (Extended Data Fig. 3e , f).
We found that approximately two-thirds of RA risk loci demonstrated pleiotropy with other human phenotypes (Extended Data Fig. 4 ), including immune-related diseases (for example, vitiligo, primary biliary cirrhosis), inflammation-related or haematological biomarkers (for example, fibrinogen, neutrophil counts) and other complex traits (for example, cardiovascular diseases).
Each of 100 non-MHC RA risk loci contains on average ,4 genes in the region of linkage disequilibrium (in total 377 genes). To prioritize systematically the most likely biological candidate gene, we devised an in silico bioinformatics pipeline. In addition to the published methods that integrate data across associated loci 7,8 , we evaluated several biological data sets to test for enrichment of RA risk genes, which helps to pinpoint a specific gene in each loci (Extended Data Figs 5, 6 and  Supplementary Tables 2-4 ).
We first conducted functional annotation of RA risk SNPs. Sixteen per cent of SNPs were in linkage disequilibrium with missense SNPs (r 2 . 0.80; Extended Data Fig. 5a , b). The proportion of missense RA risk SNPs was higher compared with a set of genome-wide common SNPs (8.0%), and relatively much higher in the explained heritability (,26.8%). Using cis-acting expression quantitative trait loci (cis-eQTL) data obtained from peripheral blood mononuclear cells (5,311 individuals) 6 and from CD4 1 T cells and CD14 1 CD16 2 monocytes (212 individuals), we found that RA risk SNPs in 44 loci showed cis-eQTL effects (false discovery rate (FDR) q or permutation P , 0.05; Extended Data Table 2 ). Second, we evaluated whether genes from RA risk loci overlapped with human primary immunodeficiency (PID) genes 14 , and observed significant overlap (14/194 5 7.2%, P 5 1.2 3 10 24 ; Fig. 1a and Extended Data Fig. 5c ). Classification categories of PID genes showed different patterns of overlap: the highest proportion of overlap was in 'immune dysregulation' (4/21 5 19.0%, P 5 0.0033) but there was no overlap in 'innate immunity'.
Third, we evaluated overlap with cancer somatic mutation genes 15 , under the hypothesis that genes with cell growth advantages may contribute to RA development. Among 444 genes with registered cancer somatic mutations 15 , we observed significant overlap with genes implicated in haematological cancers (17/251 5 6.8%, P 5 1.2 3 10 24 ; Fig. 1b and Extended Data Fig. 5d ), but not with genes implicated in non-haematological cancers (6/221 5 2.7%, P 5 0.56).
Fourth, we evaluated overlap with genes implicated in knockout mouse phenotypes 16 . Among the 30 categories of phenotypes 16 , we observed 3 categories significantly enriched with RA risk genes (P , 0.05/30 5 0.0017): 'haematopoietic system phenotype', 'immune system phenotype', and 'cellular phenotype' (Extended Data Fig. 5e ).
Last, we conducted molecular pathway enrichment analysis ( Fig. 1c and Extended Data Fig. 5f ). We observed enrichment (FDR q , 0.05) for T-cell-related pathways, consistent with cell-specific epigenetic marks, as well as enrichment for B-cell and cytokine signalling pathways (for example, interleukin (IL)-10, interferon, granulocyte-macrophage colonystimulating factor (GM-CSF)). For comparison, our previous RA GWAS meta-analysis 2 did not identify the B-cell and cytokine signalling pathways, thereby indicating that as more loci are discovered, further biological pathways are identified.
On the basis of these new findings, we adopted the following 8 criteria to prioritize each of the 377 genes from the 100 non-MHC RA risk loci ( Fig. 2 and Extended Data Fig. 6a -c): (1) genes with RA risk missense variant (n 5 19); (2) cis-eQTL genes (n 5 51); (3) genes prioritized by PubMed text mining 7 (n 5 90); (4) genes prioritized by protein-protein interaction (PPI) 8 (n 5 63); (5) PID genes (n 5 15); (6) haematological cancer somatic mutation genes (n 5 17); (7) genes prioritized by associated knockout mouse phenotypes (n 5 86); and (8) genes prioritized by molecular pathway analysis 9 (n 5 35).
Ninety-eight genes (26.0%) had a score $2, which we defined as 'candidate biological RA risk genes'. Nineteen loci included multiple biological RA risk genes (for example, IL3 and CSF2 at chromosome 5q31), whereas no biological gene was selected from 40 loci ( Supplementary  Table 5 ).
To provide empirical evidence of the pipeline, we evaluated relationships of the gene scores to independent genomic or epigenetic information. Genes with higher biological scores were more likely to be the nearest gene to the risk SNP (18.6% for gene score ,2 and 49.0% for gene score $2; P 5 2.1 3 10 28 ), and also to be included in the region where RA risk SNPs were overlapping with H3K4me3 T reg peaks (41.9% for gene score ,2 and 57.1% for gene score $2; P 5 0.034). Further, T reg cells demonstrated the largest increase in overlapping proportions with H3K4me3 peaks for increase of biological gene scores compared with other cell types (Extended Data Fig. 6d ).
Finally, we evaluated the potential role of RA genetics in drug discovery. We proposed that if human genetics is useful for drug target validation, then it should identify existing approved drugs for RA. To test this 'therapeutic hypothesis' 1 , we obtained 871 drug target genes corresponding to approved, in clinical trials or experimental drugs for human diseases 17, 18 ( Supplementary Table 6 ). We evaluated whether any of the protein products from the identified biological RA risk genes, or any genes from a direct PPI network with such protein products SNPs newly associated with P , 5.0 3 10 28 in the combined study of the stage 1 GWAS meta-analysis and the stages 2 and 3 replication studies of trans-ethnic (Europeans and Asians), European or Asian ancestry are indicated. SNPs, positions and alleles are based on the positive (1) strand of NCBI build 37. A1 represents an RA risk allele. Chr, chromosome; OR, odds ratio; 95% CI, 95% confidence interval. Full results of the studies are available in Supplementary Table 1 . Hyphens between gene names indicate that several candidate RA risk genes were included in the region. *Association results with P , 5.0 3 10 28 .
LETTER RESEARCH ( Fig. 3a) , are the pharmacologically active targets of approved RA drugs (Extended Data Fig. 7a ). Twenty-seven drug target genes of approved RA drugs demonstrated significant overlap with 98 biological RA risk genes and 2,332 genes from the expanded PPI network (18 genes overlapped; 3.7-fold enrichment by permutation analysis, P , 1.0 3 10 25 ; Fig. 3b ). For comparison, all drug target genes (regardless of disease indication) overlapped with 247 genes, which is 1.7-fold more enrichment than expected by chance, but less than 2.2-fold enrichment compared with overlap of the target genes of RA drugs (P 5 0.0035). Examples of approved RA therapies identified by this analysis include tocilizumab 19, 20 (anti-IL6R), tofacitinib 21 (JAK3 inhibitor) and abatacept 21 (CTLA4-immunoglobulin; Fig. 3c and Extended Data Fig. 8 ).
We also assessed how approved drugs for other diseases might be connected to biological RA risk genes. We highlight CDK6 and CDK4, targets of three approved drugs for different types of cancer 22 (Fig. 3d) . Supplementary Table 5 .
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In support for repurposing, one CDK6/CDK4 inhibitor, flavopiridol, has been shown to ameliorate disease activity in animal models of RA 22 . Further, the biology is plausible, as several approved RA drugs were initially developed for cancer treatment and then repurposed for RA (for example, rituximab). Although further investigations are necessary, we propose that target genes/drugs selected by this approach could represent promising candidates for novel drug discovery for RA treatment. We note that a non-random distribution of drug-to-disease indications in the databases could potentially bias our results. Namely, because RA risk genes are enriched for genes with immune function, spurious enrichment with drug targets could occur if the majority of drug indications in databases were for immune-mediated diseases or immunerelated target genes. However, such enrichment was not evident in our analysis (,11% for drug indications and ,9% for target genes; Extended Data Fig. 7b ).
Through a comprehensive genetic study with .100,000 subjects, we identified 42 novel RA risk loci and provided novel insight into RA pathogenesis. We particularly highlight the role of genetics for drug discovery. Although there have been anecdotal examples of this 1, 23 , our study provides a systematic approach by which human genetic data can be efficiently integrated with other biological information to derive biological insights and drive drug discovery.
METHODS SUMMARY
Details can be found in Methods, Extended Data Fig. 1 
The MHC region Fig. 7c ). c, Connections between RA risk SNPs (blue), biological genes (purple), genes from PPI (green) and approved RA drugs (orange). For full results, see Extended Data Fig. 8 . d, Connections between RA genes and drugs indicated for other diseases.
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(2) genotyping, quality control and genotype imputation of GWAS data; (3) genomewide meta-analysis (stage 1); (4) in silico and de novo replication studies (stages 2 and 3); (5) trans-ethnic and functional annotations of RA risk SNPs; (6) prioritization of biological candidate genes; and (7) drug target gene enrichment analysis.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper. All subjects in the stage 1, stage 2 and stage 3 studies were confirmed to be independent through analysis of overlapping SNP markers. Any duplicate subjects were removed from the stage 2 and stage 3 replication studies, leading to slightly different sample sizes compared with previous studies that used these same collections 2,3 .
METHODS
All participants provided written informed consent for participation in the study as approved by the ethical committees of each of the institutional review boards. Detailed descriptions of the study design, participating cohorts and the clinical characteristics of the RA cases are provided in detail in Extended Data Fig. 1 and Extended Data Table 1a , as well as in previous reports [2] [3] [4] . Genotyping, quality control and genotype imputation of GWAS data. Genotyping platforms and quality control criteria of GWAS, including cut-off values for sample call rate, SNP call rate, minor allele frequency (MAF), and Hardy-Weinberg equilibrium (HWE) P value, covariates in the analysis, and imputation reference panel information are provided for each study in Extended Data Table 1b . All studies were analysed based on the same analytical protocol, including exclusion of closely related subjects and outliers in terms of ancestries, as described elsewhere 3 . After applying quality control criteria, whole-genome genotype imputation was performed using 1000 Genomes Project Phase I (a) European (n 5 381) and Asian (n 5 286) data as references 11 . We excluded monomorphic or singleton SNPs or SNPs with deviation of HWE (P , 1.0 3 10 27 ) from each of the reference panels. GWAS data were split into ,300 chunks that evenly covered whole-genome regions and additionally included 300 kb of duplicated regions between neighbouring chunks. Immunochip data were split into ,2,000 chunks that included each of the targeted regions or SNPs on the array. Each chunk was pre-phased and imputed by using minimac (release stamp 2011-10-27). SNPs in the X chromosome were imputed for males and females separately. We excluded imputed SNPs that were duplicated between chunks, SNPs with MAF , 0.005 in RA cases or controls, or with low imputation score (Rsq , 0.5 for genome-wide array and , 0.7 for Immunochip) from each study. We found that imputation of Immunochip effectively increased the number of the available SNPs by 7.0 fold (from ,129,000 SNPs to ,924,000 SNPs) to cover ,12% of common SNPs (MAF . 0.05) included in the 1000 Genomes Project reference panel for European ancestry 11 . Stage 1 trans-ethnic genome-wide meta-analysis. Associations of SNPs with RA were evaluated by logistic regression models assuming additive effects of the allele dosages including top 5 or 10 principal components as covariates (if available) using mach2dat v.1.0.16 (Extended Data Table 1b ). Allele dosages of the SNPs in X chromosome were assigned as 0/1/2 for females and 0/2 for males and analysed separately. Meta-analysis was performed for the trans-ethnic study (both Europeans and Asians), European study, and Asian study separately. The SNPs available in $3 studies were evaluated in each GWAS meta-analysis, which yielded ,10 million autosomal and X-chromosomal SNPs. Information about the SNPs, including the coded alleles, was oriented to the forward strand of the NCBI build 37 reference sequence. Meta-analysis was conducted by an inverse-variance method assuming a fixed-effects model on the effect estimates (b) and the standard errors of the allele dosages using the Java source code implemented by the authors 25 . Double GC correction was carried out using the inflation factor (l GC ) obtained from the results of each GWAS and the GWAS meta-analysis 25 after removing the SNPs located 6 1 Mb from known RA loci or in the MHC region (chromosome 6, 25-35 Mb). Although there is not yet uniform consensus on the application of double GC correction, we note that potential effects of double GC correction would not be substantial in our study because of the small values of the inflation factors in the GWAS metaanalysis (l GC , 1.075 and l GC adjusted for 1,000 cases and 1,000 controls (l GC_1,000 ) , 1.005; Extended Data Table 1b ).
As for the definition of known RA risk loci in this study, we included the loci that showed significant associations in one of the previous studies (P , 5.0 3 10 28 ) or that had been replicated in independent cohorts. We consider the locus including multiple independent signals of associations as a single locus, such as the MHC locus 12 and TNFAIP3 (ref. 4 ). Although 6 of these 59 loci previously identified as known RA risk loci did not reach a suggestive level of association (defined as P , 5.0 3 10 26 ) in our stage 1 meta-analysis, previous studies have gone on to replicate most of these associations in additional samples ( Supplementary Table 1 
Thus, the number of confirmed RA risk loci is 101 (including the MHC region). Stage 2 and stage 3 replication studies. In silico (stage 2) and de novo (stage 3) replication studies were conducted using independent European and Asian subjects (Extended Data Table 1 ). The 146 loci that satisfied P , 5.0 3 10 26 in the stage 1 trans-ethnic, European or Asian GWAS meta-analysis were selected for the stage 2 in silico replication study. The SNPs that demonstrated the most significant associations were selected from each of the loci. When the SNP was not available in replication data sets, a proxy SNP with the highest linkage disequilibrium (r 2 . 0.80) was alternatively assessed. GWAS quality control, genotype imputation and association analysis were assessed in the same manner as in the stage 1 GWAS. For the 60 loci that demonstrated suggestive associations in the combined results of the stage 1 GWAS meta-analysis and the stage 2 in silico replication study but were not included as a known RA risk locus, we calculated statistical power to newly achieve a genome-wide significance threshold of P , 5.0 3 10 28 for Europeans and Asians separately, which were estimated based on the allele frequencies, ORs and de novo replication sample sizes of the populations. We then selected the top 20 SNPs with the highest statistical power for Europeans and Asians separately (in total 32 SNPs), and conducted the stage 3 de novo replication study. Genotyping methods, quality control and confirmation of subject independence in the stage 3 de novo replication study were described previously 2, 3 . The combined study of the stage 1 GWAS meta-analysis and the stages 2 and 3 replication studies was conducted by an inverse-variance method assuming a fixed-effects model 25 .
Trans-ethnic and functional annotations of RA risk SNPs. Trans-ethnic comparisons of RAF (in the reference panels), ORs and explained heritability were conducted using the results of the stage 1 GWAS meta-analysis of Europeans and Asians. Correlations of RAF and OR were evaluated using Spearman's correlation test. ORs were defined based on minor alleles in Europeans. Explained heritability was estimated by applying a liability-threshold model assuming disease prevalence of 0.5% (ref. 10) and using the RAF and OR of the population(s) according to the genetic risk model. For the population-specific genetic risk model, the RAF and OR of the same population was used. For the trans-ethnic genetic risk model, the RAF of the population but the OR of the other population was used.
Details of the overlap enrichment analysis of RA risk SNPs with H3K4me3 peaks have been described elsewhere 13 . Briefly, we evaluated whether the RA risk SNPs (outside of the MHC region) and SNPs in linkage disequilibrium (r 2 . 0.80) with them were enriched in overlap with H3K4me3 chromatin immunoprecipitation followed by sequencing (ChIP-seq) assay peaks of 34 cell types obtained from the National Institutes of Health Roadmap Epigenomics Mapping Consortium, by a permutation procedure with 310 5 iterations. Fine mapping of causal risk alleles. For fine mapping of the causal risk alleles, we selected the 31 RA risk loci where the risk SNPs yielded P , 1.0 3 10 23 in the stage 1 GWAS meta-analysis of both Europeans and Asians with the same directional effects of alleles (outside of the MHC region). For fine mapping using linkagedisequilibrium structure differences between the populations, we calculated average numbers of the SNPs in linkage disequilbrium (r 2 . 0.80) in Europeans, Asians, and in both Europeans and Asians, separately.
For fine mapping using H3K4me3 peaks of T reg primary cells, we first evaluated H3K4me3 peak overlap enrichment of the SNPs in linkage disequilbrium (in Europeans and Asians) compared with the neighbouring SNPs (62 Mb). We fixed the SNP positions but physically slid H3K4me3 peak positions by 1 kb bins within 62 Mb regions of the risk SNPs, and calculated overlap of the SNPs in linkage disequilibrium with H3K4me3 peaks for each sliding step, and evaluated the significance of overlap in the original peak positions by a one-sided exact test assuming enrichment of overlap. For the 10 loci that demonstrated significant overlap (P , 0.05), we calculated the average number of the SNPs that were in linkage disequilibrium in both Europeans and Asians and also included in H3K4me3 peaks.
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Pleiotropy analysis. We downloaded phenotype-associated SNPs and phenotype information from the National Human Genome Research Institute (NHGRI) GWAS catalogue database 26 on 31 January, 2013. We selected 4,676 significantly associated SNPs (P , 5.0 3 10 28 ) corresponding to 311 phenotypes (other than RA). We manually curated the phenotypes by combining the same but differently named phenotypes into a single phenotype (for example, from 'urate levels', 'uric acid levels' and 'renal function-related traits (urea)' to 'urate levels'), or splitting merged phenotypes into sub-categorical phenotypes (for example, from 'white blood cell types' into 'neutrophil counts', 'lymphocyte counts', 'monocyte counts', 'eosinophil counts' or 'basophil counts'). Lists of curated phenotypes and SNPs are available at http://plaza.umin.ac.jp/,yokada/datasource/software.htm.
For each of the selected NHGRI GWAS catalogue SNPs and the RA risk SNPs identified by our study (located outside of the MHC region), we defined the genetic region based on 625 kb of the SNP or the neighbouring SNP positions in moderate linkage disequilibrium with it in Europeans or Asians (r 2 . 0.50). If multiple different SNPs with overlapping regions were registered for the same phenotype, they were merged into a single region. We defined 'region-based pleiotropy' as two phenotype-associated SNPs sharing part of their genetic regions or sharing any UCSC hg19 reference gene(s) that partly overlapped each of the regions (Extended Data Fig. 4a ). We defined 'allele-based pleiotropy' as two phenotype-associated SNPs that were in linkage disequilibrium in Europeans or Asians (r 2 . 0.80). We defined the direction of an effect as 'concordant' with RA risk if the RA risk allele also leads to increased risk of the disease or increased dosage of the quantitative trait; similarly, we defined relationships as 'discordant' if the RA risk allele is associated with decreased risk of the disease phenotype (or if the RA risk allele leads to decreased dosage of the quantitative trait).
We evaluated statistical significance of region-based pleiotropy of the registered phenotypes with RA by a permutation procedure with 310 7 iterations. When one phenotype had n loci of which m loci were in region-based pleiotropy with RA, we obtained a null distribution of m by randomly selecting n SNPs from obtained NHGRI GWAS catalogue data and calculating the number of the observed regionbased pleiotropy with RA for each of the iteration steps. For estimation of the null distribution, we did not include the SNPs associated with several autoimmune diseases that were previously reported to share pleiotropic associations with RA (Crohn's disease, type 1 diabetes, multiple sclerosis, coeliac disease, systemic lupus erythematosus, ulcerative colitis and psoriasis) 2 . Prioritization of biological candidate genes from RA risk loci. For RA risk SNPs outside of the MHC region, functional annotations were conducted by Annovar (hg19). RA risk SNPs were classified if any of the SNPs in linkage disequilibrium (r 2 . 0.80) in Europeans or Asians were annotated in order of priority of missense (or nonsense), synonymous or non-coding (with or without cis-eQTL) SNPs. We also applied this SNP annotation scheme to 10,000 randomly selected genomewide common SNPs (MAF . 0.05 in Europeans or Asians).
We then assessed cis-eQTL effects by referring two eQTL data sets: the study for peripheral blood mononuclear cells (PBMCs) obtained from 5,311 European subjects 6 and newly generated cell-specific eQTL analysis for CD4 1 T cells and CD14 1 CD16 2 monocytes from 212 European subjects (ImmVar project; T.R. et al., manuscript submitted). When the RA risk SNP was not available in eQTL data sets, we alternatively used the results of best proxy SNPs in linkage disequilibrium with the highest r 2 value (.0.80). We applied the significance thresholds defined in the original studies (FDR q , 0.05 for PBMC eQTL and gene-based permutation P , 0.05 for cell-specific eQTL).
We obtained PID genes and their classification categories as defined by the International Union of Immunological Societies Expert Committee 14 , downloaded cancer somatic mutation genes from the Catalogue of Somatic Mutations in Cancer (COSMIC) database 15 , and downloaded knockout mouse phenotype labels and gene information from the Mouse Genome Informatics (MGI) database 16 on 31 January, 2013 (Supplementary Tables 2-5 ). We defined 377 RA risk genes included in the 100 RA risk loci (outside of the MHC region) according to the criteria described in the previous section (625 kb or r 2 . 0.50), and evaluated overlap with PID categories, cancer phenotypes with registered somatic mutations, and phenotype labels of knockout mouse genes with human orthologues. Statistical significance of enrichment in gene overlap was assessed by a permutation procedure with 310 6 iterations. For each iteration step, we randomly selected 100 genetic loci matched for number of nearby genes with those in non-MHC 100 RA risk loci. When one gene category had m genes overlapping with RA risk genes, we obtained a null distribution of m by calculating the number of genes in the selected loci overlapping with RA risk genes for each iteration step.
We conducted molecular pathway enrichment analysis using MAGENTA software 9 and adopting Ingenuity and BIOCARTA databases as pathway information resources. We conducted two patterns of analyses by inputting genome-wide SNP P values of the current trans-ethnic meta-analysis (stage 1) and the previous metaanalysis of RA 2 separately. As the previous meta-analysis was conducted using imputed data based on HapMap Phase II panels, we re-performed the metaanalysis using the same subjects but with newly imputed genotype data based on the 1000 Genomes Project reference panel 11 to make SNP coverage conditions identical between the meta-analyses. Significance of the molecular pathway was evaluated by FDR q values obtained from 310 5 iterations of permutations.
We scored each of the genes included in the RA risk loci (outside of the MHC region) by adopting the following eight selection criteria and calculating the number of the satisfied criteria: (1) genes for which RA risk SNPs or any of the SNPs in linkage disequilibrium (r 2 . 0.80) with them were annotated as missense variants;
(2) genes for which significant cis-eQTL of any of PBMCs, T cells or monocytes were observed for RA risk SNPs (FDR q , 0.05 for PBMCs and permutation P , 0.05 for T cells and monocytes); (3) genes prioritized by PubMed text mining using GRAIL 7 with gene-based P , 0.05; (4) genes prioritized by PPI network using DAPPLE 8 with gene-based P , 0.05; (5) PID genes 14 ; (6) haematological cancer somatic mutation genes 15 ; (7) genes for which $2 of associated phenotype labels ('haematopoietic system phenotype', 'immune system phenotype' and 'cellular phenotype'; P , 1.0 3 10 24 ) were observed for knockout mouse 16 ; and (8) genes prioritized by molecular pathway analysis using MAGENTA 9 , which were included in the significantly enriched pathways (FDR q , 0.05) with gene-based P , 0.05. Because these criteria showed weak correlations with each other (R 2 , 0.26; Extended Data Fig. 6c ), each gene was given a score based on the number of criteria that were met (scores ranging from 0-8 for each gene). We defined the genes with a score $2 as 'biological RA risk genes'.
For each gene in RA risk loci, we evaluated whether the gene was the nearest gene to the RA risk SNP within the risk locus, or whether the RA risk SNP (or SNPs in linkage disequilibrium with it) of the gene overlapped with H3K4me3 histone peaks of cell types. The difference in proportions of genes that were the nearest gene to biological RA risk genes (score $2) and non-biological genes (score ,2) was evaluated by using Fisher's exact test implemented in R statistical software (v. 2.15.2) . The difference in the proportions of genes overlapping with T reg primary cell H3K4me3 peaks between biological and non-biological genes was assessed by a permutation procedure by shuffling the overlapping status of RA risk SNPs/ loci with 310 5 iterations. Drug target gene enrichment analysis. We obtained drug target genes and corresponding drug information from DrugBank 17 and the Therapeutic Targets Database (TTD) 18 on 31 January, 2013, as well as additional literature searches. We selected drug target genes that had pharmacological activities (for the genes from DrugBank) and human orthologues, and that were annotated to any of the approved, clinical trial or experimental drugs (Supplementary Table 6 ). We manually extracted drug target genes annotated to approved RA drugs on the basis of discussions with professional rheumatologists (Extended Data Fig. 7a ). We extracted genes in direct PPI with biological RA risk genes by using the InWeb database 27 . To take account of potential dependence between PPI genes and drug target genes, overlap of biological RA risk genes and genes in direct PPI with them with drug target genes was assessed by a permutation procedure with 310 5 iterations.
Let x be the set of the biological RA risk genes and genes in direct PPI with them (n x genes), y be the set of genes with protein products that are the direct target of approved RA drugs (n y genes), and z be the set of genes with protein products that are the direct target of all approved drugs (n z genes). We defined n x>y and n x>z as the numbers of genes overlapping between x and y and between x and z, respectively. For each of 10,000 iteration steps, we randomly selected a gene set of x9 including n x genes from the entire PPI network (12,735 genes). We defined n x>y 9 and n x>z 9 as the numbers of genes overlapping between x9 and y, and between x9 and z, respectively. The distributions of n x>y 9, n x>z 9 and n x>y 9/n x>z 9 obtained from the total iterations were defined as the null distributions of n x>y , n x>z , and n x>y /n x>z , respectively. Fold enrichment of overlap with approved RA drug target genes was defined as n x>y /m(n x>y 9), where m(t) represents the mean value of the distribution of t. Fold enrichment of overlap with approved all drug target genes was defined as n x>z /m(n x>z 9). Relative fold enrichment of overlap with RA drug target genes and with all drug target genes was defined as (n x>y /n x>z )/m(n x>y 9/n x>z 9). Significance of the enrichment was evaluated by one-sided permutation tests examining n x>y , n x>z , and n x>y /n x>z in their null distributions. Web resources. Figure 1 | An overview of the study design. a, We conducted a three-stage trans-ethnic meta-analysis in total of 29,880 RA cases and 73,758 controls of European (EUR) and Asian (ASN) ancestry. The stage 1 GWAS meta-analysis included 19,234 RA cases and 61,565 controls from 22 studies, which was followed by the stage 2 in silico replication study (3,708 RA cases and 5,535 controls) and stage 3 de novo replication study (6,938 RA cases and 6,658 controls). In the combined study of stages 1-3, we identified 42 novel RA risk loci, which increased the total number of RA risk loci to 101. b, Using the 100 RA risk loci (outside of the MHC region), we conducted trans-ethnic and functional annotation of the RA risk SNPs. We constructed an in silico bioinformatics pipeline to prioritize biological candidate genes. We adopted eight criteria to score each of 377 genes in the RA risk loci: (1) RA risk missense variant; (2) cis-eQTL; (3) PubMed text mining; (4) PPI; (5) PID; (6) haematological cancer somatic mutation; (7) knockout mouse phenotype; and (8) molecular pathway. Our study also demonstrated that these biological candidate genes in RA risk loci are significantly enriched in overlap with target genes for approved RA drugs. Double GC correction was applied based on the inflation factor, l GC , which was estimated from the SNPs outside of the known RA loci and indicated in each plot. b, Manhattan plots of P values in the stage 1 GWAS meta-analysis for trans-ethnic, European and Asian ancestries. The y-axis indicates the 2log 10 (P values) of genome-wide SNPs in each GWAS meta-analysis. The horizontal grey line represents the genome-wide significance threshold of P 5 5.0 3 10 28 . The SNPs for which P values were less than 1.0 3 10 220 are indicated at the upper limit of each plot.
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Extended Data Figure 3 | Trans-ethnic and functional annotation of RA risk SNPs. a, b, Comparisons of RAF and OR values between individuals of European (EUR) and Asian (ASN) ancestry from the stage 1 GWAS metaanalysis. ORs were defined based on minor alleles in Europeans. SNPs with F ST . 0.10 or SNPs in which the 95% CI of the OR did not overlap between Europeans and Asians are coloured. OR of the SNP in the HLA-DRB1 locus ($1.5) is plotted at the upper limits of the x-and y-axes. Five loci demonstrated population-specific associations (P , 5.0 3 10 28 in one population but P . 0.05 in the other population without overlap of the 95% CI of the OR) are highlighted by red labels (rs227163 at TNFRSF9, rs624988 at CD2, rs726288 at SFTPD, rs10790268 at CXCR5 and rs73194058 at IFNGR2). c, Cumulative curve of explained heritability in each population. d, Enrichment analysis for overlap of RA risk SNPs with H3K4me3 peaks in cell types. The most significant cell type is T reg primary cells. e, Number of SNPs in the process of trans-ethnic and functional fine mapping. For 31 loci in which the risk SNPs yielded P , 1.0 3 10 23 in both populations (stage 1 GWAS), the number of candidate causal variants was reduced by 40-70% when confined by SNPs in linkage disequilibrium with the RA risk SNPs (r 2 . 0.80) in both populations (on average, from 21.9 or 37.3 SNPs in linkage disequiliberium in Europeans or Asians, to 15.0 SNPs in linkage disequilibrium in both populations). Further, for 10 loci in which candidate causal variants significantly overlapped with H3K4me3 peaks in T reg cells (P , 0.05), the average number of SNPs was further reduced by half again, from 10.4 to 5.9. f, Fine mapping in the CTLA4 locus, where the functional non-coding variant of CT60 (rs3087243) 28 showed the most significant association with RA. The top three panels indicate regional SNP associations of the locus in the stage 1 GWAS meta-analysis for trans-ethnic, European and Asian ancestries, respectively. The bottom panel indicates the change in the number of the candidate causal variants in each process of fine mapping. Trans-ethnic fine mapping of candidate causal variants decreased the number of candidate variants from 44 (linkage disequilibrium in Asians) and 27 (linkage disequilibrium in Europeans) to 21 (linkage disequilibrium in both populations). As these SNPs were significantly enriched in overlap with H3K4me3 peaks in T reg cells compared with the surrounding SNPs (P 5 0.037), we confined the candidate variants into nine by additionally selecting the SNPs included in H3K4me3 peaks. CT60 was included in these finally selected nine SNPs, and also located at the vicinity of a H3K4me3 peak summit (indicated by a red arrow). Although 44% of all RA risk SNPs had cis-eQTL, 9 of them overlapped with missense or synonymous variants but 35 of them did not overlap as indicated by asterisks. A list of cis-eQTL SNPs and genes can be found in Extended Data Table 2 . c, Overlap of RA risk genes with human PID and defined categories.
d, Overlap of RA risk genes with cancer somatic mutation genes. In addition to the categories of all cancers, haematological cancers and non-haematological cancers, cancer types that showed overlap with $2 of RA risk genes are indicated. e, Overlap of RA risk genes with knockout mouse phenotypes. Knockout mouse phenotypes that satisfied significant enrichment with RA risk genes are indicated in bold (P , 0.05/30 5 0.0017). f, Molecular pathway analysis of RA GWAS results. Molecular pathways that showed significant enrichment in either the current stage 1 trans-ethnic GWAS meta-analysis or the previous GWAS meta-analysis of RA 2 are indicated in bold (FDR q , 0.05).
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